Tandem Diabetes Care annual gross margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tandem Diabetes Care's gross margin was 53.81% for fiscal 2025.
View full Tandem Diabetes Care company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 53.81% | +1.74 pp |
| 2024 | 2024-12-31 | 52.07% | +2.90 pp |
| 2023 | 2023-12-31 | 49.17% | −2.37 pp |
| 2022 | 2022-12-31 | 51.54% | −1.99 pp |
| 2021 | 2021-12-31 | 53.53% | +1.30 pp |
| 2020 | 2020-12-31 | 52.23% | −1.38 pp |
| 2019 | 2019-12-31 | 53.60% | +4.75 pp |
| 2018 | 2018-12-31 | 48.85% | +7.87 pp |
| 2017 | 2017-12-31 | 40.98% | +12.98 pp |
| 2016 | 2016-12-31 | 28.00% | −8.48 pp |
| 2015 | 2015-12-31 | 36.49% | +5.82 pp |
| 2014 | 2014-12-31 | 30.67% | +9.41 pp |
| 2013 | 2013-12-31 | 21.26% | +75.73 pp |
| 2012 | 2012-12-31 | −54.46% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 56.87% | +4.58 pp |
| Q1 2026 | 2026-03-31 | 55.33% | +4.82 pp |
| Q4 2025 | 2025-12-31 | 57.67% | +1.96 pp |
| Q3 2025 | 2025-09-30 | 53.88% | +2.78 pp |
| Q2 2025 | 2025-06-30 | 52.29% | +1.46 pp |
| Q1 2025 | 2025-03-31 | 50.51% | +1.12 pp |
| Q4 2024 | 2024-12-31 | 55.71% | +8.30 pp |
| Q3 2024 | 2024-09-30 | 51.09% | +2.74 pp |
| Q2 2024 | 2024-06-30 | 50.83% | −1.10 pp |
| Q1 2024 | 2024-03-31 | 49.39% | +0.45 pp |
| Q4 2023 | 2023-12-31 | 47.41% | −4.98 pp |
| Q3 2023 | 2023-09-30 | 48.35% | −2.70 pp |
| Q2 2023 | 2023-06-30 | 51.93% | +1.02 pp |
| Q1 2023 | 2023-03-31 | 48.95% | −2.84 pp |
| Q4 2022 | 2022-12-31 | 52.39% | −1.77 pp |
| Q3 2022 | 2022-09-30 | 51.05% | −2.81 pp |
| Q2 2022 | 2022-06-30 | 50.91% | −2.80 pp |
| Q1 2022 | 2022-03-31 | 51.78% | −0.18 pp |
| Q4 2021 | 2021-12-31 | 54.16% | +0.28 pp |
| Q3 2021 | 2021-09-30 | 53.86% | +1.02 pp |
| Q2 2021 | 2021-06-30 | 53.71% | +3.92 pp |
| Q1 2021 | 2021-03-31 | 51.96% | +0.64 pp |
| Q4 2020 | 2020-12-31 | 53.88% | −1.72 pp |
| Q3 2020 | 2020-09-30 | 52.84% | −0.70 pp |
| Q2 2020 | 2020-06-30 | 49.79% | −3.72 pp |
| Q1 2020 | 2020-03-31 | 51.33% | +0.79 pp |
| Q4 2019 | 2019-12-31 | 55.60% | +1.09 pp |
| Q3 2019 | 2019-09-30 | 53.54% | +6.43 pp |
| Q2 2019 | 2019-06-30 | 53.51% | +9.30 pp |
| Q1 2019 | 2019-03-31 | 50.54% | +8.73 pp |
| Q4 2018 | 2018-12-31 | 54.51% | +11.16 pp |
| Q3 2018 | 2018-09-30 | 47.11% | +3.15 pp |
| Q2 2018 | 2018-06-30 | 44.21% | +6.69 pp |
| Q1 2018 | 2018-03-31 | 41.81% | +6.22 pp |
| Q4 2017 | 2017-12-31 | 43.35% | +8.54 pp |
| Q3 2017 | 2017-09-30 | 43.97% | +56.79 pp |
| Q2 2017 | 2017-06-30 | 37.52% | +1.95 pp |
| Q1 2017 | 2017-03-31 | 35.59% | +1.05 pp |
| Q4 2016 | 2016-12-31 | 34.81% | −11.40 pp |
| Q3 2016 | 2016-09-30 | −12.83% | −47.91 pp |
| Q2 2016 | 2016-06-30 | 35.57% | +5.00 pp |
| Q1 2016 | 2016-03-31 | 34.54% | +11.73 pp |
| Q4 2015 | 2015-12-31 | 46.22% | +9.68 pp |
| Q3 2015 | 2015-09-30 | 35.08% | +2.54 pp |
| Q2 2015 | 2015-06-30 | 30.57% | −3.06 pp |
| Q1 2015 | 2015-03-31 | 22.81% | +12.08 pp |
| Q4 2014 | 2014-12-31 | 36.54% | +24.94 pp |
| Q3 2014 | 2014-09-30 | 32.54% | −0.04 pp |
| Q2 2014 | 2014-06-30 | 33.63% | +26.29 pp |
| Q1 2014 | 2014-03-31 | 10.74% | −26.64 pp |
| Q4 2013 | 2013-12-31 | 11.59% | — |
| Q3 2013 | 2013-09-30 | 32.57% | — |
| Q2 2013 | 2013-06-30 | 7.34% | — |
| Q1 2013 | 2013-03-31 | 37.38% | — |
Over the last five reported fiscal years, Tandem Diabetes Care's gross margin increased from 52.23% to 53.81%, a change of +1.58 percentage points. The latest reported quarter, Q2 2026, shows 56.87%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tandem Diabetes Care filings at SEC.gov ↗